Appropriateness of Antimicrobial Selection for Treatment of Pneumonia in Selected Public Hospitals of Eastern Ethiopia: A Cross-sectional Study

Overview

Journal SAGE Open Med

Publisher Sage Publications

Specialty General Medicine

Date 2023 Apr 17

PMID 37065976

Authors

Abera Jambo

Dumessa Edessa

Fuad Adem

Tigist Gashaw

Affiliations

Soon will be listed here.

Abstract

Objective: Inappropriate antimicrobial use leads to drug resistance and poor clinical outcomes. Considering the lack of data regarding the drug use patterns in the treatment of pneumonia in selected study areas, the authors felt compelled to assess the appropriateness of antimicrobial usage in the treatment of pneumonia at Hiwot Fana Specialized Comprehensive University Hospital and Jugal Hospital from May 1 to 31, 2021.

Methods: A cross-sectional retrospective study was conducted using the medical cards of 693 admitted patients with pneumonia. The collected data were analyzed using SPSS version 26. Bivariable and multivariable logistic regression analyses were used to identify the factors associated with an initial inappropriate antibiotic use. A value of 0.05 was used to determine the statistical significance of the association using an adjusted odds ratio with 95% confidence interval.

Results: Of the total participants, 116 (16.74%, 95% confidence interval: 14.1-19.6) of them received an initial inappropriate antimicrobial regimen. Ceftriaxone plus azithromycin was the most prescribed antimicrobial agent. Patients who were younger than 5 years (adjusted odds ratio = 1.71; 95% confidence interval: 1.00-2.94), between 6 and 14 years (adjusted odds ratio = 3.14; 95% confidence interval: 1.64-6.00), and older than 65 years (adjusted odds ratio = 2.97; 95% confidence interval: 1.07-2.66), with comorbid conditions (adjusted odds ratio = 1.74; 95% confidence interval: 1.10-2.72) and prescribed by medical interns (adjusted odds ratio = 1.80; 95% confidence interval: 1.14-2.84) were associated with an initial inappropriate antimicrobial use.

Conclusion: Around one out of every six patients had received initial inappropriate treatments. Adherence to the recommendation of guidelines and attention to extreme-aged groups and comorbidity may improve antimicrobial use.

Citing Articles

Assessment of inappropriate use of antibiotics and contributing factors in Awi Administrative Zone, Northwestern Amhara regional State, Ethiopia.

Atnkut B, Nigussie A, Gebreamanule B, Kumera B, Astatkie T New Microbes New Infect. 2025; 63():101557.

PMID: 39807160 PMC: 11728071. DOI: 10.1016/j.nmni.2024.101557.

References

Mei H, Wang J, Che H, Wang R, Cai Y . The clinical efficacy and safety of vancomycin loading dose: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(43):e17639. PMC: 6824660. DOI: 10.1097/MD.0000000000017639. View

Leblanc J, ElSherif M, Ye L, MacKinnon-Cameron D, Ambrose A, Hatchette T . Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015. BMJ Open Respir Res. 2020; 7(1). PMC: 7078693. DOI: 10.1136/bmjresp-2019-000550. View

Mora-Ochomogo M, Lohans C . β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates. RSC Med Chem. 2021; 12(10):1623-1639. PMC: 8528271. DOI: 10.1039/d1md00200g. View

Ajmi S, Aase K . Physicians' clinical experience and its association with healthcare quality: a systematised review. BMJ Open Qual. 2021; 10(4). PMC: 8573657. DOI: 10.1136/bmjoq-2021-001545. View

Arda B, Sipahi O, Yamazhan T, Tasbakan M, Pullukcu H, Tunger A . Short-term effect of antibiotic control policy on the usage patterns and cost of antimicrobials, mortality, nosocomial infection rates and antibacterial resistance. J Infect. 2007; 55(1):41-8. DOI: 10.1016/j.jinf.2007.02.014. View

Rubinstein E, Cammarata S, Oliphant T, Wunderink R . Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001; 32(3):402-12. DOI: 10.1086/318486. View

English M, Fredericks C, Milanesio N, Rohowsky N, Xu Z, Jenta T . Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother. 2012; 56(4):2037-47. PMC: 3318370. DOI: 10.1128/AAC.05596-11. View

Arias-Fernandez L, Gil-Prieto R, Gil-de-Miguel A . Incidence, mortality, and lethality of hospitalizations for community-acquired pneumonia with comorbid cardiovascular disease in Spain (1997-2015). BMC Infect Dis. 2020; 20(1):477. PMC: 7336298. DOI: 10.1186/s12879-020-05208-y. View

Jain S, Self W, Wunderink R, Fakhran S, Balk R, Bramley A . Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015; 373(5):415-27. PMC: 4728150. DOI: 10.1056/NEJMoa1500245. View

10.

Chen T, Lu P, Lin C, Lin W, Chen Y . Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011; 15(3):e211-6. DOI: 10.1016/j.ijid.2010.11.008. View

11.

Wise L . Risks and benefits of (pharmaco)epidemiology. Ther Adv Drug Saf. 2014; 2(3):95-102. PMC: 4110815. DOI: 10.1177/2042098611404920. View

12.

Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A . Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Clin Infect Dis. 2008; 46(10):1499-509. DOI: 10.1086/587519. View

13.

Kato H, Hagihara M, Asai N, Shibata Y, Koizumi Y, Yamagishi Y . Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2021; 24:98-105. DOI: 10.1016/j.jgar.2020.12.009. View

14.

Gajdacs M, Paulik E, Szabo A . Knowledge, Attitude and Practice of Community Pharmacists Regarding Antibiotic Use and Infectious Diseases: A Cross-Sectional Survey in Hungary (KAPPhA-HU). Antibiotics (Basel). 2020; 9(2). PMC: 7168197. DOI: 10.3390/antibiotics9020041. View

15.

Jain S, Williams D, Arnold S, Ampofo K, Bramley A, Reed C . Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015; 372(9):835-45. PMC: 4697461. DOI: 10.1056/NEJMoa1405870. View

16.

Hamao N, Ito I, Konishi S, Tanabe N, Shirata M, Oi I . Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial. BMC Pulm Med. 2020; 20(1):160. PMC: 7275365. DOI: 10.1186/s12890-020-01198-4. View

17.

Zeng X, Lin J . Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria. Front Microbiol. 2013; 4:128. PMC: 3660660. DOI: 10.3389/fmicb.2013.00128. View

18.

Lipsitch M, Samore M . Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis. 2002; 8(4):347-54. PMC: 2730242. DOI: 10.3201/eid0804.010312. View

19.

Aston S, Ho A, Jary H, Huwa J, Mitchell T, Ibitoye S . Etiology and Risk Factors for Mortality in an Adult Community-acquired Pneumonia Cohort in Malawi. Am J Respir Crit Care Med. 2019; 200(3):359-369. PMC: 6680311. DOI: 10.1164/rccm.201807-1333OC. View

20.

Ashagrie D, Genet C, Abera B . Vancomycin-resistant enterococci and coagulase-negative staphylococci prevalence among patients attending at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia. PLoS One. 2021; 16(4):e0249823. PMC: 8031390. DOI: 10.1371/journal.pone.0249823. View